MedPage Today on MSN

Could This Be the First Disease-Modifying Drug in Bronchiectasis?

CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...
The American Journal of Managed Care

Integrating Brensocatib and CT Scans Into NCF Bronchiectasis Management: James Chalmers, MBChC, PhD

The use of CT scans is moving beyond a simple diagnostic tool for non–cystic fibrosis bronchiectasis to become a practical ...
Yahoo Finance

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

New York, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight Insmed’s BRINSUPRI (brensocatib) has ...
Yahoo

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri. File Photo by John Angelillo/UPI For the first ...
pharmaphorum

CHMP backs first drug for lung disease bronchiectasis

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...
Monthly Prescribing Reference

Brensocatib Gets Priority Review for Non-Cystic Fibrosis Bronchiectasis

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
Pulmonology Advisor

Brensocatib Beneficial in Bronchiectasis Regardless of Patient’s COPD Status

Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with ...

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...
Yahoo Finance

Non-Cystic Fibrosis Bronchiectasis Market Research 2025-2035, Competitive Analysis of AstraZeneca, Sanofi, Insmed, Boehringer Ingelheim, Zambon, Chiesi, Haisco, Regeneron

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has ...
Business Wire

Non–Cystic Fibrosis Bronchiectasis (NCFB) FDA Grants “Fast-Track” and “QIPD” to Zambon for Colistimethate Sodium Powder for Nebulizer Solution Delivered by the I-neb ...

BRESSO, Italy--(BUSINESS WIRE)--Zambon announced that colistimethate sodium powder for nebulizer solution, delivered by the I-neb AAD system obtained QIDP and “Fast Track” designation by the FDA for ...